Healthcare provider profile · identity verified

David Pazer, MD

Internal Medicine · RIDGEFIELD, CT · NPI 1710022264

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	527	153
Rosuvastatin Calcium	Rosuvastatin Calcium	389	126
Levothyroxine Sodium	Levothyroxine Sodium	357	90
Amlodipine Besylate	Amlodipine Besylate	267	77
Metoprolol Succinate	Metoprolol Succinate	208	58
Losartan Potassium	Losartan Potassium	206	54
Pantoprazole Sodium	Pantoprazole Sodium	192	59
Ezetimibe	Ezetimibe	160	48
Simvastatin	Simvastatin	157	42
Metformin Hcl	Metformin Hcl	154	40
Lisinopril	Lisinopril	153	44
Tamsulosin Hcl	Tamsulosin Hcl	149	41
Furosemide	Furosemide	135	43
Eliquis	Apixaban	131	34
Escitalopram Oxalate	Escitalopram Oxalate	131	36
Hydrochlorothiazide	Hydrochlorothiazide	126	43
Gabapentin	Gabapentin	125	26
Mirtazapine	Mirtazapine	123	27
Famotidine	Famotidine	101	26
Trazodone Hcl	Trazodone Hcl	95	35
Memantine Hcl	Memantine Hcl	94	13
Pioglitazone Hcl	Pioglitazone Hcl	92	28
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	87	27
Quetiapine Fumarate	Quetiapine Fumarate	83	12
Pravastatin Sodium	Pravastatin Sodium	80	27
Metoprolol Tartrate	Metoprolol Tartrate	77	22
Allopurinol	Allopurinol	76	23
Ozempic	Semaglutide	75	15
Valsartan	Valsartan	74	25
Donepezil Hcl	Donepezil Hcl	67	14
Omeprazole	Omeprazole	67	25
Sertraline Hcl	Sertraline Hcl	67	17
Finasteride	Finasteride	63	15
Albuterol Sulfate Hfa	Albuterol Sulfate	62	33
Baclofen	Baclofen	58	suppressed
Montelukast Sodium	Montelukast Sodium	58	16
Clopidogrel	Clopidogrel Bisulfate	55	15
Xarelto	Rivaroxaban	54	suppressed
Bupropion Xl	Bupropion Hcl	53	17
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	43	13
Synthroid	Levothyroxine Sodium	43	15
Breo Ellipta	Fluticasone/Vilanterol	42	15
Carvedilol	Carvedilol	41	12
Jardiance	Empagliflozin	41	17
Alendronate Sodium	Alendronate Sodium	38	11
Zolpidem Tartrate	Zolpidem Tartrate	38	21
Entresto	Sacubitril/Valsartan	35	suppressed
Fluticasone Propionate	Fluticasone Propionate	32	12
Spironolactone	Spironolactone	31	suppressed
Januvia	Sitagliptin Phosphate	30	suppressed
Alprazolam	Alprazolam	28	16
Caspofungin Acetate	Caspofungin Acetate	27	suppressed
Daptomycin	Daptomycin	27	suppressed
Divalproex Sodium	Divalproex Sodium	27	suppressed
Insulin Lispro Kwikpen U-100	Insulin Lispro	27	suppressed
Atenolol	Atenolol	25	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	25	suppressed
Duloxetine Hcl	Duloxetine Hcl	25	suppressed
Lorazepam	Lorazepam	25	suppressed
Citalopram Hbr	Citalopram Hydrobromide	24	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	24	suppressed
Nystatin	Nystatin	24	suppressed
Tramadol Hcl	Tramadol Hcl	24	suppressed
Cephalexin	Cephalexin	23	suppressed
Potassium Chloride	Potassium Chloride	23	suppressed
Pregabalin	Pregabalin	23	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	21	suppressed
Autoshield Duo Pen Needle	Pen Needle,dual Safety,diabetc	21	suppressed
Budesonide	Budesonide	21	suppressed
Prednisone	Prednisone	21	18
Testosterone	Testosterone	21	suppressed
Diazepam	Diazepam	20	suppressed
Levetiracetam	Levetiracetam	20	suppressed
Mounjaro	Tirzepatide	20	suppressed
Paroxetine Hcl	Paroxetine Hcl	20	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	19	suppressed
Zosyn	Piperacillin-Tazo-Dextrose,iso	19	suppressed
Ipratropium-Albuterol	Ipratropium/Albuterol Sulfate	17	suppressed
Ketoconazole	Ketoconazole	17	suppressed
Meloxicam	Meloxicam	17	suppressed
Midodrine Hcl	Midodrine Hcl	17	suppressed
Nuedexta	Dextromethorphan Hbr/Quinidine	17	suppressed
Doxycycline Monohydrate	Doxycycline Monohydrate	16	suppressed
Azithromycin	Azithromycin	15	14
Clonazepam	Clonazepam	15	suppressed
Farxiga	Dapagliflozin Propanediol	15	suppressed
Irbesartan	Irbesartan	15	suppressed
Oxycodone Hcl	Oxycodone Hcl	15	suppressed
Wixela Inhub	Fluticasone Propion/Salmeterol	15	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	14	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	14	suppressed
Glipizide Er	Glipizide	14	suppressed
Lamotrigine	Lamotrigine	14	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	14	suppressed
Metformin Hcl Er	Metformin Hcl	14	suppressed
Naltrexone Hcl	Naltrexone Hcl	14	suppressed
Rybelsus	Semaglutide	14	suppressed
Torsemide	Torsemide	14	suppressed
Bupropion Hcl Sr	Bupropion Hcl	13	suppressed
Enoxaparin Sodium	Enoxaparin Sodium	13	suppressed
Nifedipine Er	Nifedipine	13	suppressed
Sucralfate	Sucralfate	13	suppressed
Chlorthalidone	Chlorthalidone	12	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	12	suppressed
Fosfomycin Tromethamine	Fosfomycin Tromethamine	12	suppressed
Incruse Ellipta	Umeclidinium Bromide	12	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	12	11
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	12	suppressed
Symbicort	Budesonide/Formoterol Fumarate	12	suppressed
Arexvy	Rsvpref3 Antigen/As01e/Pf	11	suppressed
Meclizine Hcl	Meclizine Hcl	11	suppressed
Ofloxacin	Ofloxacin	11	suppressed
Olmesartan-Hydrochlorothiazide	Olmesartan/Hydrochlorothiazide	11	suppressed
Propranolol Hcl	Propranolol Hcl	11	suppressed
Tolterodine Tartrate Er	Tolterodine Tartrate	11	suppressed
Toujeo Solostar	Insulin Glargine,hum.Rec.Anlog	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error